The Ministry of Health, Labor and Welfare (MHLW) on November 22 proposed two rules designed to address windfall price rises enjoyed by cheaply sold generics - a problematic fallout from the current three price-band grouping rule.The rules formed part of…
BUSINESS
Luring Big Pharma with GPCR Work, Sosei Heptares Treads Its Own Path to Pursue Small Molecule Targets
Sosei Group’s unique drug discovery platform for G protein-coupled receptor (GPCR)-targeted compounds is attracting a growing list of big pharma companies, with CEO Shinichi Tamura stressing that small molecules are still “the high road” in pharmaceuticals despite drug makers’ uphill…
To read the full story
Related Article
BUSINESS
- Wholesalers’ Bid-Rigging Scandal Might Have Been Exposed via Leniency Program, Further Cases Could Be Laid Bare: Lawyer
December 6, 2019
- Mochida, Idorsia Hook Up on Insomnia Drug in Japan
December 6, 2019
- Fujifilm’s US Bioscience Site Now Up and Running
December 6, 2019
- Daiichi Sankyo Reps Continue Heavy Pitches for Tarlige in September: Impact Track
December 6, 2019
- Keytruda Remains No. 1 in November Japan Drug Ranking: Encise
December 6, 2019
A raft of new medicines will be added to Japan’s NHI price list on November 19, with a key reimbursement…
Combined sales of eight major Japanese drug makers grew nearly 26% year on year in April-September, pushed up by the acquisition of Shire by Takeda Pharmaceutical. Even excluding the industry leader, though, seven firms still collectively eked out a slight…
Indian generic maker Lupin is casting off Kyowa Pharmaceutical Industry, which it acquired in 2007. Forking over 57.4 billion yen…
As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
While the digital transformation may only be in its infancy in the pharmaceutical industry, the winds of change are here. It’s only a matter of time until customers and patients demand a higher level of service, experience, and connectivity from…